Metagenomi, Inc. (MGX)
After hours:
| Previous Close | 4.6700 |
| Open | 4.7500 |
| Bid | 3.4200 x 200 |
| Ask | 5.6300 x 200 |
| Day's Range | 4.3300 - 4.7600 |
| 52 Week Range | 3.3400 - 12.7400 |
| Volume | |
| Avg. Volume | 93,911 |
| Market Cap | 167.465M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.0600 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.00 |
GlobeNewswireMetagenomi to Present at the 2024 Jefferies Global Healthcare Conference
EMERYVILLE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that Metagenomi CEO and Founder, Brian C. Thomas, will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:30 a.m. Eastern Time. The Company will also participate in one-on-one investor m
- GlobeNewswire
Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results
Late breaking presentation at World Federation of Hemophilia (WFH) World Congress on investigational development program in Hemophilia A; development candidate nomination anticipated in mid-year 2024; 12-month non-human primate durability data expected in 2H 2024 Presentation at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting demonstrated MGX base editing systems expanded genome targetability by 5-fold compared to SpCas9 Base Editors Presentation at ASGCT demonstrated MGX RNA-me
- GlobeNewswire
Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems
Enhances strategic flexibility and control of key gene editing technologies and programsEMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced it has regained full global rights to research, develop, manufacture, and commercialize its wholly-owned gene editing technologies, in
